Manufacturing, Packaging & Detailing Market Research Reports & Industry Analysis
Current Good Manufacturing Practices (cGMPs) refers to the regulations enforced by the FDA. The cGMPs provide for systems that assure proper design, monitoring, and control of manufacturing processes and facilities.
Adherence to the cGMP regulations assures the identity, strength, quality, and purity of drug products by requiring that manufacturers of medications adequately control manufacturing operations. This includes establishing strong quality management systems, obtaining appropriate quality raw materials, establishing robust operating procedures, detecting and investigating product quality deviations, and maintaining reliable testing laboratories. This formal system of controls at a pharmaceutical company, if adequately put into practice, helps to prevent instances of contamination, mix-ups, deviations, failures, and errors. This assures that drug products meet their quality standards.
The cGMP requirements were established to be flexible in order to allow each manufacturer to decide individually how to best implement the necessary controls by using scientifically sound design, processing methods, and testing procedures. The flexibility in these regulations allows companies to use modern technologies and innovative approaches to achieve higher quality through continual improvement.
- Use of RFID in serialized unique packaging numbering to authenticate and check for recall/expiry status.
- Use of X-ray and metal detection systems to detect glass, stone, bone, rubber and other contaminants
- Use of checkweighers and sorters
- Use of baggers capable of handling, opening and sealing bags manufactured from specialist sterile films and papers.
- Use of quality control labeling systems
It is important to note that cGMPs are minimum requirements. Many pharmaceutical manufacturers are already implementing comprehensive, modern quality systems and risk management approaches that exceed these minimum standards. This is important because a consumer cannot detect through smell, touch, or sight if a drug product is safe or if it will work.
Manufacturing, Packaging & Detailing Industry Research & Market Reports
-
Analytical Standards
... CAGR of 6.6% over the analysis period 2024-2030. Pharmaceutical & Life Science Analysis Application, one of the segments analyzed in the report, is expected to record a 7.4% CAGR and reach US$611.4 Million by the ... Read More
-
Pharmaceutical Contract Manufacturing
... at a CAGR of 5.2% over the analysis period 2024-2030. Pharmaceutical, one of the segments analyzed in the report, is expected to record a 5.9% CAGR and reach US$93.8 Billion by the end of the ... Read More
-
Ibuprofen API
... CAGR of 0.9% over the analysis period 2024-2030. Arthritis Application, one of the segments analyzed in the report, is expected to record a 1.4% CAGR and reach US$392.0 Million by the end of the analysis ... Read More
-
ePedigree Software
... CAGR of 17.3% over the analysis period 2024-2030. On-Premise Deployment, one of the segments analyzed in the report, is expected to record a 16.5% CAGR and reach US$4.6 Billion by the end of the analysis ... Read More
-
Alpha-1 Antitrypsin Drugs
... at a CAGR of 9.6% over the analysis period 2024-2030. Prolastin C Drugs, one of the segments analyzed in the report, is expected to record a 9.4% CAGR and reach US$2.1 Billion by the end ... Read More
-
Isosorbide
... 7.4% over the analysis period 2024-2030. PEIT, one of the segments analyzed in the report, is expected to record a 9.1% CAGR and reach US$439.5 Million by the end of the analysis period. Growth in ... Read More
-
Alopecia Drugs
... CAGR of 5.5% over the analysis period 2024-2030. Topical Drugs, one of the segments analyzed in the report, is expected to record a 5.4% CAGR and reach US$8.4 Billion by the end of the analysis ... Read More
-
Attapulgite
... 6.9% over the analysis period 2024-2030. Colloidal grade, one of the segments analyzed in the report, is expected to record a 8.5% CAGR and reach US$320.0 Million by the end of the analysis period. Growth ... Read More
-
Beta-Sitosterol
... 8.1% over the analysis period 2024-2030. Food Ingredients, one of the segments analyzed in the report, is expected to record a 7.7% CAGR and reach US$510.6 Million by the end of the analysis period. Growth ... Read More
-
Nanocapsules
... 6.3% over the analysis period 2024-2030. Oncology, one of the segments analyzed in the report, is expected to record a 7.1% CAGR and reach US$2.0 Billion by the end of the analysis period. Growth in ... Read More
-
Bio Decontamination
... CAGR of 4.5% over the analysis period 2024-2030. Equipment, one of the segments analyzed in the report, is expected to record a 4.2% CAGR and reach US$122.1 Million by the end of the analysis period. ... Read More
-
Healthcare Contract Management Software
... 2030, growing at a CAGR of 19.3% over the analysis period 2024-2030. Software, one of the segments analyzed in the report, is expected to record a 20.1% CAGR and reach US$7.1 Billion by the end ... Read More
-
Healthcare Contract Research Organization (CRO)
... Billion by 2030, growing at a CAGR of 5.4% over the analysis period 2024-2030. Clinical, one of the segments analyzed in the report, is expected to record a 5.4% CAGR and reach US$68.2 Billion by ... Read More
-
Healthcare Distribution
... CAGR of 13.5% over the analysis period 2024-2030. Pharmaceutical, one of the segments analyzed in the report, is expected to record a 13.3% CAGR and reach US$2.3 Trillion by the end of the analysis period. ... Read More
-
Native Collagen
... CAGR of 5.9% over the analysis period 2024-2030. Bovine, one of the segments analyzed in the report, is expected to record a 6.5% CAGR and reach US$130.6 Million by the end of the analysis period. ... Read More
-
Pharmaceutical Grade Silica Gel
... 2030, growing at a CAGR of 8.6% over the analysis period 2024-2030. Desiccant, one of the segments analyzed in the report, is expected to record a 8.5% CAGR and reach US$81.0 Million by the end ... Read More
-
Sarcoma Drugs
... CAGR of 7.6% over the analysis period 2024-2030. Targeted Therapy, one of the segments analyzed in the report, is expected to record a 7.4% CAGR and reach US$1.9 Billion by the end of the analysis ... Read More
-
Pharmaceutical Hot Melt Extrusion Equipment
... Million by 2030, growing at a CAGR of 4.3% over the analysis period 2024-2030. Twin Screw Extruders, one of the segments analyzed in the report, is expected to record a 4.1% CAGR and reach US$28.0 ... Read More
-
Manual Filling Equipment
... at a CAGR of 6.7% over the analysis period 2024-2030. Food & Beverages, one of the segments analyzed in the report, is expected to record a 6.8% CAGR and reach US$1.1 Billion by the end ... Read More
-
RFID in Healthcare
... at a CAGR of 14.6% over the analysis period 2024-2030. Tags, one of the segments analyzed in the report, is expected to record a 16.1% CAGR and reach US$8.5 Billion by the end of the ... Read More
-
Pharmaceutical Chemicals
... CAGR of 4.9% over the analysis period 2024-2030. OTC, one of the segments analyzed in the report, is expected to record a 4.0% CAGR and reach US$16.8 Billion by the end of the analysis period. ... Read More
-
Antibacterial Drugs
... CAGR of 3.8% over the analysis period 2024-2030. ß-lactams, one of the segments analyzed in the report, is expected to record a 4.1% CAGR and reach US$35.4 Billion by the end of the analysis period. ... Read More
-
Chemotherapy-induced Nausea and Vomiting Drugs
... Billion by 2030, growing at a CAGR of 5.1% over the analysis period 2024-2030. Serotonin Receptor Antagonist, one of the segments analyzed in the report, is expected to record a 5.3% CAGR and reach US$2.0 ... Read More
-
Chronic Kidney Disease (CKD) Drugs
... Billion by 2030, growing at a CAGR of 4.5% over the analysis period 2024-2030. Antihypertensives, one of the segments analyzed in the report, is expected to record a 4.5% CAGR and reach US$6.0 Billion by ... Read More
-
Heart Failure Drugs
... at a CAGR of 12.4% over the analysis period 2024-2030. The U.S. Market is Estimated at US$2.4 Billion While China is Forecast to Grow at 16.3% CAGR The Heart Failure Drugs market in the U.S. ... Read More
Research Assistance
